Goldman Sachs’s Ligand Pharmaceuticals LGND Stock Holding History

Goldman Sachs’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-64,120	Closed	-$3.81M	–	5603
2020 Q3	$3.81M	Sell	64,120 -12,183	-16%	-$831K	﹤0.01%	3102
2020 Q2	$5.32M	Buy	+76,303	New	+$4.84M	﹤0.01%	2758
2017 Q2	–	Sell	-25,648	Closed	-$1.69M	–	6869
2017 Q1	$1.69M	Buy	+25,648	New	+$1.69M	﹤0.01%	3917
2014 Q3	–	Sell	-40,075	Closed	-$1.56M	–	7191
2014 Q2	$1.56M	Buy	+40,075	New	+$1.63M	﹤0.01%	4248
2014 Q1	–	Sell	-50,014	Closed	-$1.64M	–	6857
2013 Q4	$1.64M	Buy	50,014 +37,831	+311%	+$1.23M	﹤0.01%	4282
2013 Q3	$329K	Sell	12,183 -67,967	-85%	-$1.91M	﹤0.01%	5499
2013 Q2	$1.87M	Buy	+80,150	New	+$1.44M	﹤0.01%	3793

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's LGND Position: Q2 2026 in Review

Goldman Sachs reduced its Ligand Pharmaceuticals (LGND) stake by 15% in Q2 2026, selling an estimated $13.6M and leaving 323,245 shares worth $102M. The position accounts for 0.01% of the portfolio, ranked #1210.

Goldman Sachs first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Goldman Sachs held 323,245 shares of Ligand Pharmaceuticals worth $102M as of Q2 2026.
Goldman Sachs sold 57,866 Ligand Pharmaceuticals shares in Q2 2026, an estimated $13.6M.
Ligand Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1210 holding.
Goldman Sachs first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.